Boston, US-based XRHealth is leading the deal, acquiring NeuroReality of the Netherlands for an undisclosed sum, combining their products and expertise in the use of XR and virtual reality software ...

Cassava then released the altered data in a press release and investor deck, which led the SEC to allege that the company and ...

CD40 agonists have had mixed results in cancer to date, with Roche discontinuing its selicrelumab candidate after ...

GLP-1 agonist Wegovy (semaglutide) brought in DKK 17.3 billion ($2.49 billion) in the period, restoring earlier levels of ...

It is all over bar the shouting win for the US election, with Donald Trump set to claim the Presidency, potentially with the ...

Read Deep Dive: Patients & Partnerships in full pharmaphorum’s digital magazine Deep Dive provides objective, issue-driven ...

BEAM-101 is an ex vivo genetic therapy delivered as part of an autologous haematopoietic stem cell transplant (HSCT) after a conditioning chemotherapy regimen to destroy the bone marrow and allow it ...

AstraZeneca's shares have fallen more than 8% on speculation about an anti-corruption probe in China, its second-largest ...

Field medical education before launch is linked to greater launch success, improving treatment adoption by up to 50%. New ...

Incyte filed a lawsuit to try to block the launch of Leqselvi, claiming that the drug infringed a US patent (No. 9,662,335) ...

Lawyers for AstraZeneca, Bristol-Myers Squibb, and Johnson & Johnson argued at a panel hearing in Philadelphia late last week ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated ...